SEP. 2. 2. 2006 September the

Sheet

Equivatent of Form PTO/SB/08A (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/618,299		
Filing Date	July 11, 2003		
First Named Inventor	James G. Barsoum		
Art Unit	1633		
Examiner Name	Robert M. Kelly		
Attorney Docket Number	2159 0830001/FTH/SAS		

			U.S. PATENT DO	OCUMENTS	
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
		Number-Kind Code ^{2 (If Known)}			or Relevant Figures Appear
TUK	USI	6,696,423	02/24/2004	Barsoum et al.	
PUK	US2	2003/0229042 A1	12/11/2003	Barsoum et al.	
				•	
	<u> </u>				
	Ì				
				· · · · · · · · · · · · · · · · · · ·	
					
					
	 		 	·	
			 		
	 	· · · · · · · · · · · · · · · · · · ·			-
			 		
			 		
-		 	 		· · · · · · · · · · · · · · · · · · ·
	<u></u>				1

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
		Country Code ¹ Number ⁴ Kind Code ³ (if known)	·	•	Relevant Passages or		
					Relevant Figures Appear	T ⁶	
	<u> </u>						
<u> </u>							

582791v1

	Examiner Signature	Toland. Killy	Date Considered	5/	18/07	
--	-----------------------	---------------	--------------------	----	-------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant: 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SEP 2 2 2008

PTO/SB/08B (07-06) Approved for use through 09/30/2006, OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1 PAPENS Complete if Known **Application Number** 10/618,299 FIRST SUPPLEMENTAL Filing Date July 11, 2003 INFORMATION DISCLOSURE First Named Inventor James G. Barsoum STATEMENT BY APPLICANT Art Unit 1633 (Use as many sheets as necessary) **Examiner Name** Robert M. Kelly Sheet of Attorney Docket Number 2159.0830001/EJH/SAS

	· · · · · · · · · · · · · · · · · · ·	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
MK	NPL1	Brunner, K.T., et al., "Blood Clearance of P ₃₂ -Labeled Vesicular Stomatitis and NewCastle Disease Viruses by the Reticuloendothelial System in Mice," J. Immunol., 85:99-105, American Association of Immunologists (1960)	
	NPL2	Cai, P., et al., "Methyl palmitate: Inhibitor of phagocytosis in primary rat Kupffer cells," Toxicol. 210:197-204, Elsevier Ireland Ltd. (June 2005)	
	NPL3	Dachs, G.U., et al., "Targeting Gene Therapy to Cancer: a Review," Oncol. Res. 9:313-325, Cognizant Communication Corporation (1997)	
	NPL4	Fahimi, H.D., "The Fine Structural Localization of Endogenous and Exogenous Peroxidase Activity in Kupffer Cells of Rat Liver," <i>J. Cell Biol.</i> 47:247-262, Rockefeller University Press (1970)	
	NPL5	Kim, A., et al., "Uptake of Viruses by Kupffer Cells Isolated from Human Liver," Lancet North Am. Ed. 2:585-586, Lancet Publishing Group (1980)	
	NPL6	Kolb-Bachofen, V., "Uptake of Toxic Silica Particles by Isolated Rat Liver Macrophages (Kupffer Cells) Is Receptor Mediated and Can Be Blocked by Competition," J. Clin. Invest. 90:1819-1824, The American Society for Clinical Investigation, Inc. (1992)	
	NPL7	Laurent, N., et al., "Uptake by rat liver and intracellular fate of plasmid DNA complexed with poly-L-lysine or poly-D-lysine," FEBS Lett. 443:61-65, Federation of European Biochemical Societies (1999)	
	NPL8	Kuzmin, A.I., et al., "Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo," Gene Ther. 4:309-316, Stockton Press (1997)	
V	NPL9	Marianneau, P., et al., "Infection of Primary Cultures of Human Kupffer Cells by Dengue Virus: No Viral Progeny Synthesis, but Cytokine Production Is Evident," J. Virol. 73:5201-5206, American Society for Microbiology (1999)	
MK	NPL10	McCuskey, R.S., et al., "Kupffer Cell Function in Host Defense," Rev. Infect. Dis. 9:S616-S619, The University of Chicago (1987)	

Examiner		Date	
		1 5000	. 1 . 1
Signature	10kg //. 12kg	Considered	5/18/07
1 5 1	l	- Communica	7/'UIST

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-08)

Approved for use through 09/30/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for	r form 1449B/	РТО		Complete if Known		
FIRST S	SIIDDI E	MENIT	ra i	Application Number	10/618,299	
1				Filing Date	July 11, 2003	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor	James G. Barsoum	
SIAIE				Art Unit	1633	
	(Use as many sheets as necessary)		Examiner Name	Robert M. Kelly		
Sheet	2	of	7	Attorney Docket Number	2159.0830001/EJH/SAS	

Cita	NON PATENT LITERATURE DOCUMENTS	
No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T
NPL11	Miller, N., and Vile, R., "Targeted vectors for gene therapy," FASEB J. 9:190-199, The Federation of American Societies for Experimental Biology (1995)	
NPL12	Mogensen, S.C., "Macrophages and Age-Dependent Resistance to Hepatitis Induced by Herpes Simplex Virus Type 2 in Mice," <i>Infect. Immun. 19</i> :46-50, American Society for Microbiology (1978)	
NPL13	Rentsch, M., et al., "Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat: effects on postischemic reperfusion injury, apoptotic cell death graft regeneration and survival," Transpl. Int. 18:1079-1089, European Society for Organ Transplantation (September 2005)	
NPL14	Rubin, D.H., et al., "Transport of Infectious Reovirus into Bile: Class II Major Histocompatibility Antigen-Bearing Cells Determine Reovirus Transport," J. Virol 61:3222-3226, American Society for Microbiology (1987)	
NPL15	Selgrade, M.K., and Osborn, J.E., "Role of Macrophages in Resistance to Murine Cytomegalovirus," <i>Infect. Immun. 10</i> :1383-1390, American Society for Microbiology (1974)	
NPL16	van Til, N.P., et al., "Kupffer Cells and Not Liver Sinusoidal Endothelial Cells Prevent Lentiviral Transduction of Hepatocytes," Mol. Ther. 11:26-34, The American Society of Gene Therapy (January 2005)	
NPL17	Wake, K., et al., "Cell Biology and Kinetics of Kupffer Cells in the Liver," Int. Rev. Cytol. 118:173-229, Academic Press, Inc. (1989)	
NPL18	Zenilman, M.E., et al., "Use of Ricin A-Chain to Selectively Deplete Kupffer Cells," J. Surg. Res. 45:82-89, Academic Press, Inc. (1988)	
	NPL11 NPL12 NPL13 NPL14 NPL15 NPL16 NPL17	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published Miller, N., and Vile, R., "Targeted vectors for gene therapy," FASEB J. 9:190-199, The Federation of American Societies for Experimental Biology (1995) Mogensen, S.C., "Macrophages and Age-Dependent Resistance to Hepatitis Induced by Herpes Simplex Virus Type 2 in Mice," Infect. Immun. 19:46-50, American Society for Microbiology (1978) Rentsch, M., et al., "Benefit of Kupffer cell modulation with glycine versus Kupffer cell depletion after liver transplantation in the rat: effects on postischemic reperfusion injury, apoptotic cell death graft regeneration and survival," Transpl. Int. 18:1079-1089, European Society for Organ Transplantation (September 2005) Rubin, D.H., et al., "Transport of Infectious Reovirus into Bile: Class II Major Histocompatibility Antigen-Bearing Cells Determine Reovirus Transport," J. Virol 61:3222-3226, American Society for Microbiology (1987) Selgrade, M.K., and Osborn, J.E., "Role of Macrophages in Resistance to Murine Cytomegalovirus," Infect. Immun. 10:1383-1390, American Society for Microbiology (1974) van Til, N.P., et al., "Kupffer Cells and Not Liver Sinusoidal Endothelial Cells Prevent Lentiviral Transduction of Hepatocytes," Mol. Ther. 11:26-34, The American Society of Gene Therapy (January 2005) NPL17 Wake, K., et al., "Cell Biology and Kinetics of Kupffer Cells in the Liver," Int. Rev. Cytol. 118:173-229, Academic Press, Inc. (1989) Zenilman, M.E., et al., "Use of Ricin A-Chain to Selectively Deplete Kupffer

582847v1

				<u> </u>
Examiner Signature	Rober S. Kelly	Date Considered	5/18/	07

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08B (09-05) Approved for use through 03/31/2007. OMB 0851-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Panerwork Reduction Act of 1995, no ne

Substitute for form 1449/PTO		Co	mplete if Known
SECOND SUPPLEMEN	TAI	Application Number	10/618,299
INFORMATION DISCLOSURE		Filing Date	July 11, 2003
		First Named Inventor	BARSOUM, James G.
STATEMENT BY APPLI		Art Unit	1633
(Use as many sheets as net	cessary)	Examiner Name	KELLY, Robert M.
Sheet 3 of	3	Attorney Docket Number	2159.0830001/EJH/SAS

Examiner Initials*	Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T
		number(s), publisher, city and/or country where published	1 '
ank	NPL19	Leissner, P., et al., "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism," Gene Ther. 8:49-57, Nature Publishing Group (January 2001)	
		,	
· · · · · · · · ·			
			-
619160v1		<u> </u>	

			• 1	
Examiner Signature	Robert N. Kelly	Date Considered	5/18/0	ッチ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through ditation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Comfidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.